All In Biotech

Drug Trial Radar · NCT03425539

Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease

A Multicenter, dOuble-blind, ranDomized, Placebo-controlled, Parallel-group Study to Determine the effIcacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With FabrY Disease

Last checked: Nov 19, 2026Latest source record: Aug 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 118 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

118

Actual

Start

Jun 21, 2018

Primary completion

Aug 17, 2021

Study completion Sep 2, 2021

Sponsor

Lead sponsor
Idorsia Pharmaceuticals Ltd.Industry
Sponsor type
Industry
First posted
Feb 7, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aimed to determine the efficacy and safety of lucerastat oral monotherapy in adult subjects with Fabry disease.

Conditions

  • Fabry Disease

Interventions

  • LucerastatDrug

    Hard gelatin capsules containing 250 mg of lucerastat and inactive excipients; 1000 mg (4 capsules) twice daily (b.i.d.); dose adjusted for renal function.

  • PlaceboDrug

    Placebo capsules are identical in appearance to the lucerastat capsules, and contain inactive excipients; 4 capsules b.i.d.; dose adjusted for renal function.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Neuropathic Pain Monthly Score: Change From Baseline to Month 6Time frame: From baseline to Month 6 (duration: 6 months)

Locations

49 sites in 14 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham - Nephrology Research Clinic

    Birmingham, Alabama

  • University of California Irvine

    Irvine, California

  • UCSF Benioff Children's Hospital Oakland

    Oakland, California

  • University of Florida College of Medicine - Division of Nephrology, Hypertension & Renal Transplantation

    Gainesville, Florida

  • Emory University School of Medicine; Department of Human Genetics

    Atlanta, Georgia

  • Rush University Medical Center

    Chicago, Illinois

  • University of Iowa Stead Family Children's Hospital - Division of Medical Genetics

    Iowa City, Iowa

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Infusion Associates

    Grand Rapids, Michigan

  • Duke University Medical Center

    Durham, North Carolina

  • Oregon Health and Science University

    Portland, Oregon

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Children's Hospital of Pittsburgh (UPMC)

    Pittsburgh, Pennsylvania

  • Greenwood Genetic Center

    Greenville, South Carolina

  • Research Baylor Institute of Metabolic Disease

    Dallas, Texas

  • University of Utah - Division of Medical Genetics

    Salt Lake City, Utah

  • Lysosomal and Rare Disorders Research and Treatment Center

    Fairfax, Virginia

  • Royal Melbourne Hospital - Department of Nephrology

    Parkville, Australia

  • Royal Perth Hospital, Department of Nephrology

    Perth, Australia

  • Allgemeines Krankenhaus der Stadt Wien - Universitätsklinik für Innere Medizin III - Klinische Abteilung für Nephrologie und Dialyse

    Vienna, Austria

  • University Hospital Ghent

    Ghent, Belgium

  • University Hospital Leuven

    Leuven, Belgium

  • M.A.G.I.C Clinic Ltd

    Calgary, Canada

  • Queen Elizabeth II Health Sciences Center - Halifax Infirmary - Division of Nephrology

    Halifax, Canada

  • Research Center, Hôpital Du Sacré-Coeur de Montréal

    Montreal, Canada

  • Vancouver Hospital & Health Sciences - Vancouver General Hospital

    Vancouver, Canada

  • Health Sciences Center Winnipeg

    Winnipeg, Canada

  • London Health Sciences Centre - Victoria Hospital

    London, Ontario, Canada

  • Charite Campus Virchow-Klinikum - Nephrologie und Internistische Intensivmedizin

    Berlin, Germany

  • SphinCS GmbH

    Höchheim, Germany

  • Fachinternistische Gemeinschaftspraxis Markgräferland

    Mühlheim, Germany

  • Medizinische Klinik und Poliklinik I der Universität - Schwerpunkt Nephrologie

    Würzburg, Germany

  • Hosp Alma Mater Studiorum

    Dublin, Ireland

  • ASST Monza, Hospital San Gerardo, Nephrology

    Monza, Italy

  • University of Naples Federico II (Nephrology)

    Naples, Italy

  • Hospital Academisch Medisch Centrum - Department of Internal Medicine Div. Endrocrinology and Metabolism

    Amsterdam, Netherlands

  • Haukeland University Hospital Helse Bergen HF

    Bergen, Norway

  • University Hospital in Cracow - Dep. of of Allergies and Immunology

    Krakow, Poland

  • Cardinal Wyszynski Institute of Cardiology

    Warsaw, Poland

  • Department of Pediatric Nutrition and Metabolic Diseases; The Children's Memorial Health Institute

    Warsaw, Poland

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.